异甘草酸镁联合熊去氧胆酸治疗原发性胆汁性肝硬化的临床研究(1)
摘要 目的：研究异甘草酸镁联合熊去氧胆酸治疗原发胆汁性肝硬化的临床效果。方法：选择2012年1月至2014年12月在我院接受治疗的原发性胆汁性肝硬化(Primary Biliary Cirrhosis，PBC)患者118例，按照随机数字表法分为治疗组与对照组各59例，2组患者一般资料比较差异无统计学意义(P>0.05)。对照组在常规治疗的基础上以熊去氧胆酸治疗，治疗组在对照组治疗的基础上给予异甘草酸镁。观察2组治疗前后临床症状及体征、肝生化指标、免疫球蛋白A(IgA)、免疫球蛋白G(IgG)、免疫球蛋白M(IgM)、不良反应以及临床疗效等指标。结果：2组治疗后乏力、口干、纳差、皮肤瘙痒、总胆红素(TbiL)、碱性磷酸酶(ALP)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、γ-谷氨酰转肽酶(γ-GGT)、三酰甘油(TG)、总胆固醇(TCH)、IgA、IgG、IgM等指标均优于治疗前(P<0.05)。治疗组治疗后乏力、口干、纳差、皮肤瘙痒、TBiL、ALP、ALT、AST、γ-GGT、TG、TCH、IgA、IgG、IgM等指标均优于对照组。治疗组治疗总有效率(84.75%)显著高于对照组(64.41%)。治疗组治疗不良反应发生率(6.87%)与对照组不良反应发生率(5.08%)，差异无统计学意义(P>0.05)。结论：熊去氧胆酸联合异甘草酸镁治疗PBC，可有效改善患者临床症状及体征，改善生化指标，提高免疫调节水平，且不良反应发生率低，值得应用于临床。
关键词 异甘草酸镁；熊去氧胆酸；原发胆汁性肝硬化；临床研究
Abstract Objective：To study the clinical effect of magnesium isoglycyrrhizinate combined with ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Methods：A total of 118 PBC patients in January 2014——December 2012 treated in our hospital patients were randomly divided into combined group and control group with 59 cases in each group. There were no significant differences of two groups′ general data of patients (P>0.05). On the basis of conventional therapy， the control group treated with ursodeoxycholic acid treatment， combined group were given magnesium isoglycyrrhizinate based on the treatment of control group. The clinical symptoms and signs， liver biochemical indexes， IgA， IgG， IgM， adverse reactions and clinical curative effect index of two groups were observed before and after treatment. Results：Symptoms like fatigue， dry mouth， anorexia， skin itching， TBiL， ALP， ALT， AST， GGT， TG， TCH gamma， IgA， IgG， IgM and other indicators were improved in the two groups after treatment， P<0.05， while the combined group had significantly better results than the control group， P<0.05. The total effective rate of combined group was 84.75%， significantly higher than that of the control group (64.41%)， P<0.05. The incidence rate of adverse reaction of treatment of the combined group was 6.87% and the control group was (5.08%)， the difference was not significant， P<0.05.Conclusion：Ursodeoxycholic acid combined with magnesium isoglycyrrhizinate can effectively improve PBC patients′ clinical symptoms and signs， improve the biochemical indexes of immune regulation with low adverse the reaction， which is worthy of application in clinic.
Key Words Magnesium isoglycyrrhizinate； Ursodeoxycholic acid； Primary biliary cirrhosis； Clinical research
中圖分类号：R256.4文献标识码：Adoi：10.3969/j.issn.1673-7202.2017.02.013, http://www.100md.com(郑金萍 赵英 张伯鹏)
关键词 异甘草酸镁；熊去氧胆酸；原发胆汁性肝硬化；临床研究
Abstract Objective：To study the clinical effect of magnesium isoglycyrrhizinate combined with ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Methods：A total of 118 PBC patients in January 2014——December 2012 treated in our hospital patients were randomly divided into combined group and control group with 59 cases in each group. There were no significant differences of two groups′ general data of patients (P>0.05). On the basis of conventional therapy， the control group treated with ursodeoxycholic acid treatment， combined group were given magnesium isoglycyrrhizinate based on the treatment of control group. The clinical symptoms and signs， liver biochemical indexes， IgA， IgG， IgM， adverse reactions and clinical curative effect index of two groups were observed before and after treatment. Results：Symptoms like fatigue， dry mouth， anorexia， skin itching， TBiL， ALP， ALT， AST， GGT， TG， TCH gamma， IgA， IgG， IgM and other indicators were improved in the two groups after treatment， P<0.05， while the combined group had significantly better results than the control group， P<0.05. The total effective rate of combined group was 84.75%， significantly higher than that of the control group (64.41%)， P<0.05. The incidence rate of adverse reaction of treatment of the combined group was 6.87% and the control group was (5.08%)， the difference was not significant， P<0.05.Conclusion：Ursodeoxycholic acid combined with magnesium isoglycyrrhizinate can effectively improve PBC patients′ clinical symptoms and signs， improve the biochemical indexes of immune regulation with low adverse the reaction， which is worthy of application in clinic.
Key Words Magnesium isoglycyrrhizinate； Ursodeoxycholic acid； Primary biliary cirrhosis； Clinical research
中圖分类号：R256.4文献标识码：Adoi：10.3969/j.issn.1673-7202.2017.02.013, http://www.100md.com(郑金萍 赵英 张伯鹏)
参见：首页 > 医疗版 > 疾病专题 > 消化内科 > 肝胆疾病 > 肝硬化 > 原发性胆汁性肝硬化